hmbd-001
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2021 (NCT05057013)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Receptor tyrosine-protein kinase erbB-3ANTAGONIST
ERBB3 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05910827 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | Hummingbird Bioscience, Inc., Merck KGaA |
| NCT05919537 | Phase 1 | Sep 6, 2023 | Hummingbird Bioscience, Inc. |
| NCT05057013 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2021 | Cancer Research UK, Hummingbird Bioscience, Inc., Royal Marsden Hospital NHS Trust |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hummingbird Bioscience, Inc. | For profit | 3 | 2 | 2 | 2021 |
| Cancer Research UK | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Merck KGaA | For profit | 1 | 0 | 1 | 2023 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1